Photo illustration: Axios. Photo: Courtesy of Sanofi
Sanofi wants to be an "immunology powerhouse," but that's only one part of its strategy, says global head of business development Monika Vnuk.
Why it matters: The French pharma giant will likely execute more €1 billion to €5 billion deals across immunology, vaccines, rare disease and neurology.
